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Abstract The epothilone B analog, ixabepilone, demon-
strates low susceptibility to drug resistance mechanisms
and has demonstrated clinically meaningful eYcacy in
patients refractory to other chemotherapeutic options.
Ixabepilone is approved by the FDA for treatment of
patients with metastatic breast cancer (MBC) progressing
after taxanes and anthracyclines, either in combination with
capecitabine or as monotherapy if the patient has already
progressed on capecitabine. Ixabepilone is generally well
tolerated at the approved dose and administration schedule
of 40 mg/m2 every 3 weeks. The most commonly observed
dose-limiting adverse events (AEs) associated with
ixabepilone are myelosuppression and peripheral neuropa-
thy. Dose modiWcation including dose reduction and dosing
schedule modiWcation may be utilized to manage toxicities,
but this must be based on careful hematologic, neurologic,
and liver function monitoring. Other ixabepilone dose
schedules are being evaluated to further improve the risk/
beneWt proWle. Weekly and daily schedules of ixabepilone
have shown useful eYcacy and reasonable tolerability.
A recent phase II trial compared the tolerability of ixabepi-
lone dosed once weekly (16 mg/m2 on Days 1, 8, and 15 of
each 28-day cycle) or every 3 weeks (40 mg/m2 on Day 1
of each 21-day cycle) in patients with MBC. Preliminary
data showed that both dosing schedules had an acceptable
safety proWle; however, more AEs were reported in patients
receiving ixabepilone every 3 weeks. Ixabepilone is also
being evaluated in combination with other anticancer
agents (e.g., bevacizumab and lapatinib), in earlier breast
cancer settings and in other indications.
Keywords Ixabepilone · Breast cancer · Metastatic · 
Advanced · Epothilones · Treatment schedules
Introduction
Epothilones are cytotoxic metabolites from the myxobacte-
rium  Sorangium cellulosum that stabilize microtubules.
They induce cell death by apoptosis [1] via a mechanism
that is similar to that of taxanes [2]. Ixabepilone, a novel
semisynthetic analog of epothilone B [3], has been
modiWed to retain cytotoxic activity while improving the
stability and pharmacokinetic properties of the agent. Ixab-
epilone binds to a site similar to the taxane binding site on
the  subunit of the tubulin heterodimer, but in a qualita-
tively diVerent manner than paclitaxel [4]. Ixabepilone is
able to competitively inhibit paclitaxel binding [2, 5].
Unlike taxanes, ixabepilone demonstrates low suscepti-
bility to drug resistance mechanisms, including those asso-
ciated with resistance to multiple drug classes (such as high
expression of the drug eZux proteins P-glycoprotein and
multidrug resistance protein) and those speciWcally associ-
ated with taxane resistance (such as high expression of ßIII-
tubulin, an isotype of tubulin to which taxanes cannot bind)
[6–8]. These features, coupled with the tubulin binding
diVerences between epothilones and taxanes, may open the
door for the treatment of taxane-resistant tumors [9].
Ixabepilone was approved by the FDA in October 2007
for treatment of patients with MBC progressing after tax-
anes and anthracyclines, either in combination with capecit-
abine, or as monotherapy if the patient has already
progressed on capecitabine [10]. Given ixabepilone has
been available for a number of years, we believe it useful to
review the current approved dosing. This paper summarizes
the supporting data for the current approved dosing schedule,
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as well as the other treatment schedules that have been
investigated to optimize clinical eYcacy and tolerability. In
addition, situations for which the dose of ixabepilone may
need to be altered and special administration considerations
will be discussed.
Ixabepilone monotherapy doses and schedules
The approved dose of ixabepilone for treating metastatic
breast cancer (MBC) is 40 mg/m2 infused over 3 h every
3 weeks [10]. The dose of ixabepilone is the same for
monotherapy and for combination therapy with capecita-
bine. Ixabepilone is currently supplied as a lyophilized
powder with a polyoxyethylated castor oil/ethanol (Cremo-
phor EL®) vehicle to improve solubility. Data supporting
this dosage are discussed.
Preclinical trials established that the maximum tolerated
dose (MTD) for ixabepilone was 10 mg/kg in mouse xeno-
graft models [11]. The dose shown to give equivalent expo-
sure in humans was 40 mg/m2. This dose also produced
clinically relevant antitumor activity in patients [8].
Phase I trials in patients with solid tumors assessed a
number of diVerent dosing schedules of the Cremophor-
based formulation [12]. In a study by Mani et al. [13], 40 or
50 mg/m2 dosed once every 3 weeks was recommended
for phase II trials. Once-daily dosing for 3 days (MTD
8–10 mg/m2) [14]  o r  5d a y s  ( M T D  6m g / m 2) every 3 weeks
[12] was assessed in two separate studies. More recently
(2009), Awada and colleagues [15] assessed a weekly dos-
ing schedule of MTD 25 mg/m2 as a 30-min infusion every
week continuously or 20 mg/m2 as a 1-h infusion for
3 weeks with a 1-week break.
Phase II and phase III clinical trials in heavily pre-
treated patients with MBC generally utilized a dosing
schedule of 40 mg/m2 once every 3 weeks. This regimen
was eVective and well tolerated. Table 1 summarizes the
phase II clinical trials and dosing schedules that have been
investigated (registrational and non-registrational trials
included) [16–22]. Daily ixabepilone, administered at a
dose of 8–10 mg/m2 for 3 days, did not demonstrate mean-
ingful eYcacy in patients with MBC previously treated
with taxanes, although it was well tolerated [21]. However,
in a phase II trial in patients with MBC who had not
received prior taxane treatment, the 6 mg/m2 daily schedule
(Wve consecutive days every 3 weeks) was well tolerated
and demonstrated clinically meaningful eYcacy (57% had
partial responses) [19]. Recently, Smith et al. [22] pre-
sented toxicity results from a phase II randomized trial
comparing ixabepilone dosed once weekly (Arm 1: 16 mg/m2
over 1 h on Days 1, 8, and 15 of each 28-day cycle) vs.
every 3 weeks (Arm 2: 40 mg/m2 over 3 h on Day 1 of each
21-day cycle) in patients with MBC. Preliminary data
showed that both dosing schedules had an acceptable safety
proWle; however, more adverse events (AEs) were reported
in patients in Arm 2 compared with Arm 1 (grades 3–4
treatment-related AEs: 57% vs. 22%; serious AEs: 36% vs.
28%; grades 3–4 treatment-related neutropenia: 33% vs.
5%, respectively). Other grades 3–4 treatment-related AEs
occurring in >5% of patients were reported more frequently
in Arm 2 than in Arm 1 (fatigue: 16% vs. 5%; neuropathy:
14% vs. 5%; dehydration: 10% vs. 1%; and vomiting: 6%
vs. 0%, respectively). More patients in Arm 2 discontinued
the study due to treatment-related AEs (14% vs. 7%).
Doses and schedules in combination with other agents
Ixabepilone and capecitabine
Synergistic eVects between ixabepilone and capecitabine
were demonstrated in pre-clinical studies [23]. A phase I/II
trial assessed suitable treatment schedules for combination
therapy of ixabepilone and capecitabine [24]. In the phase I,
dose escalation study, patients received either a schedule A
regimen (ixabepilone 40 mg/m2 intravenously on Day 1
plus capecitabine 1,650–2,000 mg/m2 on Days 1–14 of a
3-week cycle) or a schedule B regimen (ixabepilone
8–10 mg/m2 on Days 1–3 plus capecitabine 1,650 mg/m2
on Days 1–14 of a 3-week cycle). The MTD for schedule A
was the 40/2,000 mg/m2 dose. During phase II of the study,
this dosing schedule showed promising eYcacy (objective
response rate [ORR] = 30%) and was generally well tolerated,
with grade 3/4 events that included fatigue (34%), hand-
foot syndrome (34%), myalgia (23%), nausea (16%),
peripheral neuropathy (19%), and diarrhea/vomiting (10%).
The large (N = 752) pivotal phase III trial utilized ixab-
epilone at 40 mg/m2 infused over 3 h on Day 1 of a 3-week
cycle, in combination with oral capecitabine 2,000 mg/m2
on Days 1–14 of a 3-week cycle. Patients in the comparator
arm received capecitabine 2,500 mg/m2 alone on the same
dosing schedule [25]. The combination dose was well toler-
ated, with mostly grade 1/2 AEs that were manageable and
reversible. The most frequent grade 3/4 AEs in the combi-
nation group were peripheral sensory neuropathy, hand-
foot syndrome, fatigue, myalgia, asthenia, and diarrhea.
The capecitabine group experienced grade 3 hand-foot
syndrome and diarrhea at incidences similar to those for the
combination arm. The ORR in the preliminary analysis
was higher for the combination arm than for capecitabine
alone (35% vs. 14%; odds ratio, 3.2; P < 0.0001) [25]. This
eYcacy was conWrmed in the Wnal analysis, with response
rates of 42 and 23% for the two arms, respectively [26].
Data showed that progression-free survival (PFS) was sig-
niWcantly higher for patients receiving ixabepilone plus
capecitabine than for those receiving capecitabine aloneCancer Chemother Pharmacol (2010) 66:1005–1012 1007
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(5.3 vs. 3.8 months; HR 0.78; 95% CI, 0.67–0.91;
P = 0.0011) [26]. The dose reduction rates for the combina-
tion arm were similar to those reported for capecitabine
plus docetaxel [27]. Data from this phase III trial were fur-
ther analyzed in order to assess the “trade-oV” between tox-
icities and PFS (“Q-TWiST” analysis = quality-adjusted
time without symptoms or toxicities). Results supported a
positive risk/beneWt to combination therapy with ixabepi-
lone and capecitabine, compared with capecitabine alone
(3.8-week improvement in quality-adjusted mean survival;
P = 0.0227) in patients with advanced or MBC refractory to
anthracyclines and taxanes [28]. Further subanalysis
(pooled patients with poor prognostic features: “triple-neg-
ative” phenotype or symptomatic KPS 70–80 or post-
adjuvant rapid relapse) supported these results, aYrming a
positive risk/beneWt ratio of ixabepalone plus capecita-
bine, compared with capecitabine alone. The greatest
diVerence in quality-adjusted survival was found in the
post-adjuvant rapid relapse subgroup (45.6% vs. 36.0% for
combination vs. monotherapy, respectively; 9.6% diVer-
ence; P = 0.0007) [29].
Ixabepilone and bevacizumab
There is preclinical evidence for synergy between ixabepi-
lone and bevacizumab [30]. A recent (2009) randomized
phase II trial investigated this combination as Wrst-line ther-
apy for MBC by comparing a weekly ixabepilone-based
regimen (16 mg/m2 weekly for 3 weeks, every 4 weeks,
plus bevacizumab 10 mg/kg every 2 weeks; Arm A) and an
every-3-week ixabepilone-based regimen (40 mg/m2 every
3 weeks plus bevacizumab 15 mg/kg every 3 weeks; Arm B)
to a combination of paclitaxel and bevacizumab (90 mg/m2
weekly, plus bevacizumab at the same dose and schedule as
Arm A; Arm C) [31]. There was an automatic dose reduc-
tion of ixabepilone 40–32 mg/m2 after the fourth treatment
cycle. The preliminary analysis revealed comparable
response rates (Arm A, 50% [34.9–65.1]; Arm B, 71%
[55.7–83.6]; and Arm C, 56% [37.7–73.6]) and 24-week
PFS rates (Arm A, 75% [62.4–87.9]; Arm B, 86% [75.7–
96.4]; and Arm C, 94% [85.4–100]) for all three arms, indi-
cating that both schedules of ixabepilone are as eYcacious
as weekly paclitaxel when combined with bevacizumab.
The most signiWcant grade 3/4 AEs included peripheral
neuropathy (Arm A, 18%; Arm B, 22%; and Arm C, 25%)
and neutropenia (Arm A, 11%; Arm B, 55%; and Arm C,
22%). Febrile neutropenia rates were <2% in all arms.
The fact that rates of AEs were similar to those observed
with ixabepilone monotherapy at these schedules suggests
that ixabepilone does not exacerbate the AE proWle of
bevacizumab. Notably, although the trial investigated
ixabepilone in combination with bevacizumab, this trial is
the Wrst to compare weekly ixabepilone to the approved
every 3-week schedule. The outcomes suggest that eYcacy
and tolerability of weekly ixabepilone might be compa-
rable to the every 3-week schedule, and evaluation of
these two schedules (ixabepilone monotherapy) in MBC
is currently underway (ClinicalTrials.gov identiWer:
NCT00593827).
Ixabepilone and lapatinib
The therapeutic potential of combining ixabepilone and
lapatinib was recently (2009) evaluated in a preclinical
study in breast cancer cell lines. Results showed that the
combination of these two agents signiWcantly reduced cell
proliferation compared with the non-Her-2-ampliWed con-
trol (P < 0.001 at 120 h) [32]. Based on the favorable
results of this study, a phase I dose escalation trial of ixab-
epilone (32 mg/m2 intravenous once every 3 weeks) in
combination with lapatinib (1,000 mg orally once daily),
with or without capecitabine (1,650 mg/m2 orally twice
a day for 14 days), for up to 54 weeks depending on
response, has been initiated in patients with Her-2 positive,
taxane- and trastuzumab-resistant advanced breast cancer
(NCT00634088). At the time of this publication, patient
accrual is still underway; however, RECIST (response
evaluation criteria in solid tumors) responses have been
conWrmed in two of the Wrst three patients enrolled in this
trial [32].
Predicting response: gene expression patterns
Recent studies have investigated the use of gene expression
patterns to predict response to ixabepilone. Baselga et al.
[33] evaluated the safety, eYcacy, and genomic predictors
of neoadjuvant ixabepilone therapy (40 mg/m2, 3-h infu-
sion every 21 days, up to four cycles) in a single-arm, phase
II study in patients with invasive breast cancer. Investiga-
tors identiWed estrogen receptor (ER) and microtubule-
associated protein tau as predictive markers for pathologic
complete response to ixabepilone as neoadjuvant therapy
(tau gene expression inversely correlated with ixabepilone
sensitivity). Further, data from Horak et al. [34] indicated a
higher III-tubulin expression in patients with “triple-nega-
tive” (negative or low expression of ER, PR, and HER2)
breast cancer with basal-like tumors (breast cancer subtype
deWned by gene expression and protein expression proWles;
often considered synonymous with triple-negative breast
cancer). Investigators noted that III-tubulin overexpres-
sion might contribute to the aggressiveness of “triple-nega-
tive” breast cancer and that increased levels may be a
predictor of response to treatment with ixabepilone. These
studies indicate that the use of gene expression analysis
prior to initiating ixabepilone therapy maybe be used toCancer Chemother Pharmacol (2010) 66:1005–1012 1009
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select patients who might derive clinical beneWt from this
treatment.
Dose modiWcations reductions
Cytotoxic chemotherapy requires balancing risk and ben-
eWt. Dose modiWcation is used to manage the toxicities
associated with therapy relative to the patient’s ability
to tolerate the therapeutic regimen. Dose modiWcation to
mitigate toxicity can be achieved either by reducing the
dose administered, increasing/delaying the time between
treatment periods, or altering the infusion time in order to
maintain drug exposure but limit the peak plasma drug
concentration often associated with toxic events.
In the clinical setting
Dose modiWcations of ixabepilone were necessary in many
clinical trials to mitigate the AEs experienced by study par-
ticipants or patients. Although 50 mg/m2 had been identi-
Wed as the MTD in one phase I trial, the dose in two
subsequent phase II trials was reduced from 50 to 40 mg/m2
to reduce the incidence of myelosuppression and mucositis.
Additionally, in these studies, the 1-h infusion was length-
ened to 3 h due to treatment-limiting neurotoxicity with the
shorter infusion time [17, 18]. Data from these studies
led to the use of a 3-h infusion of ixabepilone at 40
mg/m2 in subsequent clinical trials and is the approved
dosing as monotherapy and in combination with capecitabine
[12, 18, 25].
In the phase II registrational trial of ixabepilone mono-
therapy in MBC patients following a taxane, anthracycline,
and capecitabine, dose reductions to 32 or 25 mg/m2 were
made based on tolerability to ixabepilone in the previous
cycle [16]. Seventy percent of patients received ¸90% of
their planned relative dose intensity, and 80% of the cycles
in the trial were administered at 40 mg/m2 as planned.
In the pivotal phase III ixabepilone/capecitabine combi-
nation trial, 51 and 45% of patients in the combination arm
required dose reduction of ixabepilone and capecitabine,
respectively, compared with dose reductions in 37% of
patients in the single-agent capecitabine group [25]. The
majority of patients received ¸70% of their planned rela-
tive dose intensity: in the combination group, 88 and 62%
received ¸70% of their relative ixabepilone and capecita-
bine (2,000 mg/m2) dose intensity, respectively, compared
with 82% in the capecitabine group (2,500 mg/m2).
In clinical practice
The main dose-limiting AEs in patients treated with ixab-
epilone are neutropenia and peripheral sensory neuropathy.
Both of the AEs are manageable, reversible, and responsive
to dose reduction or delay [10]. However, patients with
¸grade 2 neuropathy were excluded from the ixabepilone
studies, and caution should be used when treating patients
with diabetes mellitus or pre-existing peripheral neuropa-
thy. In patients who have baseline neutrophil count <1,500
cells/mm3, or baseline platelet count <100,000 cells/mm3,
ixabepilone is contraindicated.
Combination therapy with ixabepilone and capecitabine
is contraindicated for patients whose levels of aspartate
aminotransferase (AST) or alanine aminotransferase (ALT)
exceed 2.5 times the upper limit of normal (ULN) or
patients whose bilirubin exceeds ULN. Based on liver
enzyme levels, patients may receive ixabepilone mono-
therapy at a reduced dose. However, the ixabepilone pre-
scribing information provides speciWc guidelines for dose
reduction or delay in several situations, including AEs,
impaired hepatic function, and potential drug–drug interac-
tions (Table 2) [10]. Doses for patients whose body surface
area exceeds 2.2 m2 should be calculated based on 2.2 m2
[10]. In order to ensure that each patient is receiving the
optimal dose, all patients should be routinely monitored for
AEs that may signal that a dose reduction is necessary;
i.e., regular complete blood counts, neurological exams, and
liver function tests [10]. There is no antidote for ixabepi-
lone overdose [10], and patients should be monitored and
oVered supportive care for any presenting clinical manifes-
tations. Overdosage has been reported for one patient who
received 100 mg/m2 (total 185 mg); however, the eVects
were minor (grade 1 fatigue and myalgia), and the patient
made a full recovery [10].
Drug interactions
Ixabepilone is a weak inhibitor of human CYP3A4, but it
is not expected to alter the plasma concentrations of other
drugs [10]. Its main route of metabolism is via CYP3A4,
and substances that inhibit CYP3A4 activity may decrease
metabolism, thereby increasing plasma concentrations of
ixabepilone. When ixabepilone is coadministered with
strong inhibitors of CYP3A4, such as ketoconazole,
itraconazole, ritonavir, amprenavir, indinavir, nelWna-
vir, delavirdine, and voriconazole, there is a signiWcant
increase in exposure to ixabepilone, and alternative ther-
apeutic agents that do not inhibit CYP3A4 should be con-
sidered. In cases where coadministration of a strong
CYP3A4 inhibitor cannot be avoided, a 50% dose reduc-
tion of ixabepilone should be considered in order to
adjust the ixabepilone area under the curve to that
observed in the absence of concurrent CYP3A4 inhibi-
tors, and patients should be monitored closely for acute
toxicities [10].1010 Cancer Chemother Pharmacol (2010) 66:1005–1012
123
Alternatively, coadministration of substances that induce
CYP3A4 activity, such as dexamethasone, phenytoin, car-
bamazepine, rifampin, and phenobarbital, may lead to sub-
therapeutic levels of ixabepilone, as they may increase
ixabepilone metabolism, leading to a decrease in plasma
concentration. In these patients, therapeutic agents with low
enzyme induction potential for coadministration with ixab-
epilone may be considered. St. John’s Wort should be
avoided, as its eVect on ixabepilone plasma concentrations
is unpredictable [10].
Other administration issues
The Cremophor vehicle of ixabepilone can elicit hypersen-
sitivity reactions (HSRs), but these can be prevented if
patients receive oral H1 and H2 antihistamines approxi-
mately 1 h prior to infusion [10, 12]. In contrast to standard
formulations of the taxanes, corticosteroid premedication is
not mandatory before ixabepilone infusion, unless the
patient has experienced a previous hypersensitivity reaction
to ixabepilone [10]. In patients who have a known history
of severe hypersensitivity reactions to a drug formulated
with Cremophor, ixabepilone is contraindicated.
The initial labeling in 2007 recommended that, after
reconstitution, ixabepilone be further diluted using only Lac-
tated Ringer’s Injection, USP. This restriction was deemed
necessary in order to maintain ixabepilone at a pH between
6.0 and 9.0, in order to maintain its stability. New labeling
released in 2009 permits two alternative choices for infusion
liquids, including PLASMA-LYTE A Injection, pH 7.4, or
0.9% Sodium Chloride Injection, USP, with the pH adjusted
to between 6.0 and 9.0 using two molar equivalents (mEq)
Sodium Bicarbonate Injection, USP. In order to obtain the
desired pH, 2 ml of an 8.4% w/v solution or 4 ml of a 4.2%
w/v solution of sodium bicarbonate must be added to each
250- or 500-ml bag of Sodium Chloride Injection before the
addition of reconstituted ixabepilone.
Summary and conclusions
Clinically meaningful eYcacy with ixabepilone is demon-
strated in patients refractory to other chemotherapeutic
Table 2 Recommended 
ixabepilone dose reductions 
and treatment 
discontinuations [10]
Issue Recommendations
Monotherapy OR combination therapy dose modiWcations
Non-hematologic adverse eventsa
Grade 2 neuropathy lasting ¸7 days Decrease dose by 20%
Grade 3 neuropathy lasting <7 days Decrease dose by 20%
Grade 2 neuropathy lasting ¸7d a y s ,  
or disabling neuropathy
Discontinue treatment
Any grade 3 toxicity other than neuropathy Decrease dose by 20%
Transient grade 3 arthralgia/myalgia No change in dose
Transient grade 3 fatigue No change in dose
Grade 3 hand-foot syndrome No change in dose
Any grade 4 toxicity Discontinue treatment
Hematologic adverse eventsa
Neutrophils <500 cells/mm3 for ¸7 days Decrease dose by 20%
Febrile neutropenia Decrease dose by 20%
Platelets <25,000/mm3 Decrease dose by 20%
Platelets <50,000/mm3 with bleeding Decrease dose by 20%
Potential drug interactions
Concomitant strong CYP3A4 inhibitor Decrease dose to 20 mg/m2
Monotherapy dose modiWcations
Baseline hepatic impairment
AST and ALT ·2.5 and bilirubin ·1 £ ULNb No change in dose of monotherapy 
or combination therapy
AST and ALT ·10 and bilirubin ·1.5 £ ULNb,c Decrease monotherapy dose to 32 mg/m2
AST and ALT ·10 and bilirubin >1.5–·3 £ ULNb,c Decrease monotherapy dose to 20–30 mg/m2
Combination therapy dose modiWcations
Baseline hepatic impairment
AST or ALT >2.5 or bilirubin >1 £ ULNb Combination therapy is contraindicated
ALT alanine aminotransferase, 
AST aspartate aminotransferase, 
ULN upper limit of normal
a Toxicities graded in accor-
dance with the National Cancer 
Institute (NCI) Common termi-
nology criteria for adverse 
events (CTCAE v3.0)
b Excludes patients whose total 
bilirubin is elevated due to 
Gilbert’s disease
c Applies to ixabepilone mono-
therapy only. Ixabepilone and 
capecitabine combination 
therapy is contraindicated in this 
settingCancer Chemother Pharmacol (2010) 66:1005–1012 1011
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options. Ixabepilone is generally well tolerated at the
approved dose and administration schedule of 40 mg/m2
every 3 weeks. The most commonly observed dose-limiting
AEs associated with ixabepilone are myelosuppression and
peripheral neuropathy (primarily sensory). Dose modiWca-
tion including dose reduction and dosing schedule modiW-
cation may be utilized to manage toxicities, but this must be
based on careful hematologic, neurologic, and liver func-
tion monitoring. Other ixabepilone dose schedules are
being evaluated to further improve risk/beneWt, and weekly
and daily schedules have shown useful eYcacy and reason-
able tolerability. Ixabepilone is also being evaluated in
combination with other anticancer agents, in earlier breast
cancer settings and in other indications.
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